Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEONNASDAQ:BFRINASDAQ:INDPNYSE:MNK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.58-4.4%$0.49$0.38▼$269.28$6.81M0.38998,663 shs206,716 shsBFRIBiofrontera$0.57-6.6%$0.74$0.54▼$2.22$5.31M0.37927,192 shs173,794 shsINDPIndaptus Therapeutics$0.34-15.9%$0.46$0.31▼$2.89$6.41M1.49199,094 shs796,663 shsMNKMallinckrodt$0.34$0.75▼$6.42$1.58MN/A2.62 million shs39,227 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%+7.87%+31.81%-23.20%-99.47%BFRIBiofrontera0.00%-10.91%-17.40%-41.56%-47.71%INDPIndaptus Therapeutics0.00%-8.78%-28.38%-59.88%-87.80%MNKMallinckrodt0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEONAEON Biopharma2.3716 of 5 stars3.50.00.00.00.61.71.9BFRIBiofrontera2.4282 of 5 stars3.53.00.00.02.50.01.3INDPIndaptus Therapeutics3.6195 of 5 stars3.55.00.00.03.31.71.3MNKMallinckrodtN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0062,400.00% UpsideBFRIBiofrontera 3.00Buy$2.75382.46% UpsideINDPIndaptus Therapeutics 3.00Buy$8.502,425.25% UpsideMNKMallinckrodt 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MNK, BFRI, AEON, and INDP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BFRIBiofronteraBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $2.75(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/ABFRIBiofrontera$38.00M0.14N/AN/A$3.16 per share0.18INDPIndaptus TherapeuticsN/AN/AN/AN/A$1.44 per shareN/AMNKMallinckrodtN/AN/AN/AN/A$47.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M$298.123.20N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)BFRIBiofrontera-$20.13M-$2.26N/AN/AN/A-36.31%-565.73%-96.64%8/13/2025 (Estimated)INDPIndaptus Therapeutics-$15.42M-$1.49N/AN/AN/AN/A-177.27%-141.06%8/11/2025 (Estimated)MNKMallinckrodtN/A-$116.19N/AN/AN/A-82.59%20.32%2.49%N/ALatest MNK, BFRI, AEON, and INDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BFRIBiofrontera-$0.14-$0.47-$0.33-$0.47$10.55 million$8.59 million5/14/2025Q1 2025INDPIndaptus Therapeutics-$0.41-$0.32+$0.09-$0.32N/AN/A3/13/2025Q4 2024INDPIndaptus Therapeutics-$0.41-$0.38+$0.03-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/AMNKMallinckrodtN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22BFRIBiofronteraN/A1.530.94INDPIndaptus TherapeuticsN/A3.423.42MNKMallinckrodt1.180.570.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%BFRIBiofrontera10.08%INDPIndaptus Therapeutics7.06%MNKMallinckrodt83.74%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%BFRIBiofrontera1.20%INDPIndaptus Therapeutics29.50%MNKMallinckrodt0.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.31 million74.37 millionNot OptionableBFRIBiofrontera709.45 million7.73 millionNo DataINDPIndaptus Therapeutics616.03 million9.96 millionNot OptionableMNKMallinckrodt2,70013.17 million13.13 millionNot OptionableMNK, BFRI, AEON, and INDP HeadlinesRecent News About These CompaniesMallinckrodt and Endo Advance Key Milestones in Strategic MergerMay 19, 2025 | msn.comMalvern-Based Endo Progresses Toward Mallinckrodt Merger CompletionMay 15, 2025 | msn.comMallinckrodt and Endo Announce Significant Progress in Proposed MergerMay 14, 2025 | finance.yahoo.comEndo, Inc.: Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial GuidanceMay 7, 2025 | finanznachrichten.deMalvern-Based Endo Approves $3.5M in Retention Bonuses for Executives Ahead of MergerApril 29, 2025 | msn.comEndo board approves millions in bonuses to keep key execs amid Mallinckrodt mergerApril 21, 2025 | bizjournals.comMallinckrodt plc to Report Earnings Results for First Quarter 2025April 11, 2025 | finance.yahoo.comMalvern’s Endo Enters Into Agreement to Merge with Mallinckrodt in $6 Billion DealMarch 17, 2025 | msn.comMallinckrodt, a pharmaceutical giant launched in St. Louis, to take over Endo in $6.7B dealMarch 17, 2025 | stltoday.comMallinckrodt and Endo Announce Merger to Build Diversified Pharmaceuticals PowerhouseMarch 16, 2025 | msn.comMallinckrodt and Endo to combine after emerging from bankruptcy linked to opioid crisisMarch 15, 2025 | ft.comPharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock DealMarch 15, 2025 | msn.comTroubled drugmakers Mallinckrodt, Endo Officially Announce $6.7B MergerMarch 13, 2025 | biospace.comDrugmakers Mallinckrodt and Endo to merge in nearly $7 billion dealMarch 13, 2025 | msn.comMallinckrodt, Endo to combine in $7B dealMarch 13, 2025 | biopharmadive.comMallinckrodt and Endo sign $6.7bn merger dealMarch 13, 2025 | finance.yahoo.comMallinckrodt, Endo look to carve out brighter future through $6.7B mergerMarch 13, 2025 | fiercepharma.comWachtell, Davis Polk Steer Mallinckrodt's $6.7 Billion Merger With EndoMarch 13, 2025 | news.bloomberglaw.comEndo agrees to merge with Mallinckrodt in deal valued at almost $7BMarch 13, 2025 | bizjournals.comMallinckrodt, Endo Merger to Create Diversified Pharmaceuticals FirmMarch 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNK, BFRI, AEON, and INDP Company DescriptionsAEON Biopharma NASDAQ:AEON$0.58 -0.03 (-4.38%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.60 +0.02 (+4.17%) As of 05/30/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Biofrontera NASDAQ:BFRI$0.57 -0.04 (-6.59%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.61 +0.04 (+6.32%) As of 05/30/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Indaptus Therapeutics NASDAQ:INDP$0.34 -0.06 (-15.85%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$0.35 +0.01 (+2.79%) As of 05/30/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Mallinckrodt NYSE:MNKMallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
